| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
|
N Engl J Med
|
2003
|
10.57
|
|
2
|
Coronary intervention for persistent occlusion after myocardial infarction.
|
N Engl J Med
|
2006
|
8.74
|
|
3
|
Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both.
|
N Engl J Med
|
2005
|
6.86
|
|
4
|
Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium.
|
Circulation
|
2011
|
6.36
|
|
5
|
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials.
|
Lancet
|
2002
|
5.04
|
|
6
|
Apixaban with antiplatelet therapy after acute coronary syndrome.
|
N Engl J Med
|
2011
|
4.81
|
|
7
|
Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure.
|
J Am Coll Cardiol
|
2005
|
3.53
|
|
8
|
Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
|
JAMA
|
2004
|
2.89
|
|
9
|
STICH (Surgical Treatment for Ischemic Heart Failure) trial enrollment.
|
J Am Coll Cardiol
|
2010
|
2.39
|
|
10
|
Under-use of secondary prevention medication in acute coronary syndrome patients treated with in-hospital coronary artery bypass graft surgery.
|
N Z Med J
|
2011
|
2.08
|
|
11
|
PHARMAC and the statin debacle.
|
N Z Med J
|
2006
|
2.07
|
|
12
|
Maori have worse outcomes after coronary artery bypass grafting than Europeans in New Zealand.
|
N Z Med J
|
2013
|
1.96
|
|
13
|
Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study.
|
JACC Cardiovasc Interv
|
2009
|
1.75
|
|
14
|
Cardiogenic shock caused by right ventricular infarction: a report from the SHOCK registry.
|
J Am Coll Cardiol
|
2003
|
1.71
|
|
15
|
The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
|
J Am Coll Cardiol
|
2006
|
1.71
|
|
16
|
The management of acute coronary syndrome patients across New Zealand in 2012: results of a third comprehensive nationwide audit and observations of current interventional care.
|
N Z Med J
|
2013
|
1.60
|
|
17
|
Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomes.
|
Eur Heart J
|
2006
|
1.59
|
|
18
|
Physical activity in patients with stable coronary heart disease: an international perspective.
|
Eur Heart J
|
2013
|
1.53
|
|
19
|
Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials.
|
JACC Cardiovasc Interv
|
2011
|
1.50
|
|
20
|
Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
|
Eur Heart J
|
2004
|
1.46
|
|
21
|
Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?
|
Circulation
|
2002
|
1.43
|
|
22
|
Acute Coronary Syndrome patients in New Zealand receive less invasive management when admitted to hospitals without invasive facilities.
|
N Z Med J
|
2004
|
1.29
|
|
23
|
Management of patients admitted with an Acute Coronary Syndrome in New Zealand: results of a comprehensive nationwide audit.
|
N Z Med J
|
2004
|
1.24
|
|
24
|
Patients admitted with an acute coronary syndrome (ACS) in New Zealand in 2007: results of a second comprehensive nationwide audit and a comparison with the first audit from 2002.
|
N Z Med J
|
2010
|
1.15
|
|
25
|
Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study.
|
Eur Heart J
|
2008
|
1.15
|
|
26
|
ACS patients in New Zealand experience significant delays to access cardiac investigations and revascularisation treatment especially when admitted to non-interventional centres: results of the second comprehensive national audit of ACS patients.
|
N Z Med J
|
2010
|
1.12
|
|
27
|
Higher mortality in women undergoing coronary artery bypass grafting.
|
N Z Med J
|
2013
|
1.03
|
|
28
|
Effect of switching antithrombin agents for primary angioplasty in acute myocardial infarction: the HORIZONS-SWITCH analysis.
|
J Am Coll Cardiol
|
2011
|
1.01
|
|
29
|
Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study.
|
Eur J Prev Cardiol
|
2012
|
0.93
|
|
30
|
Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender.
|
Clin Pharmacol Ther
|
2002
|
0.92
|
|
31
|
Utility of cardiac biomarkers for the diagnosis of type V myocardial infarction after coronary artery bypass grafting: insights from serial cardiac MRI.
|
Heart
|
2011
|
0.91
|
|
32
|
Cardiac tamponade in the fibrinolytic era: analysis of >100,000 patients with ST-segment elevation myocardial infarction.
|
Am Heart J
|
2006
|
0.88
|
|
33
|
Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups.
|
Heart
|
2006
|
0.88
|
|
34
|
Comparison of renal function and cardiovascular risk following acute myocardial infarction in patients with and without diabetes mellitus.
|
Am J Cardiol
|
2008
|
0.87
|
|
35
|
Noninvasive, medical management for non-ST-elevation acute coronary syndromes.
|
Am Heart J
|
2008
|
0.86
|
|
36
|
Editorial: why inhibition of lipoprotein-associated phospholipase A2 has the potential to improve patient outcomes.
|
Curr Opin Cardiol
|
2010
|
0.86
|
|
37
|
Coronary disease in indigenous populations: summary from the CSANZ indigenous Cardiovascular Health Conference.
|
Heart Lung Circ
|
2010
|
0.84
|
|
38
|
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
|
Lancet
|
2002
|
0.84
|
|
39
|
Antiplatelet drug nonresponsiveness.
|
Am Heart J
|
2008
|
0.84
|
|
40
|
Poor outcomes after fibrinolytic therapy for ST-segment elevation myocardial infarction: impact of age (a meta-analysis of a decade of trials).
|
J Thromb Thrombolysis
|
2006
|
0.83
|
|
41
|
Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction.
|
Vasc Health Risk Manag
|
2007
|
0.82
|
|
42
|
The evolving role of direct thrombin inhibitors in acute coronary syndromes.
|
J Am Coll Cardiol
|
2003
|
0.80
|
|
43
|
2007 addendum to the National Heart Foundation of Australia/Cardiac Society of Australia and New Zealand Guidelines for the management of acute coronary syndromes 2006.
|
Med J Aust
|
2008
|
0.80
|
|
44
|
Complex valve disease: pre-surgical functional capacity evaluation using peak oxygen consumption.
|
J Heart Valve Dis
|
2009
|
0.79
|
|
45
|
Improving cardiovascular care for indigenous populations.
|
Heart Lung Circ
|
2010
|
0.78
|
|
46
|
Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study.
|
Am Heart J
|
2006
|
0.78
|
|
47
|
Overview and determinants of cardiovascular disease in indigenous populations.
|
Heart Lung Circ
|
2010
|
0.77
|
|
48
|
Predictors of stroke within 30 days in patients with non-ST-segment elevation acute coronary syndromes.
|
Eur Heart J
|
2006
|
0.77
|
|
49
|
Lack of relationship between obesity and mortality or morbidity after coronary artery bypass grafting.
|
N Z Med J
|
2013
|
0.77
|
|
50
|
Swallowed partial dentures.
|
J R Soc Med
|
2004
|
0.76
|
|
51
|
The role of natriuretic peptides in patients with chronic complex (mixed or multiple) heart valve disease.
|
Congest Heart Fail
|
2010
|
0.76
|
|
52
|
The relationship between meteorological conditions and index acute coronary events in a global clinical trial.
|
Int J Cardiol
|
2013
|
0.76
|
|
53
|
The Cardiac Society Inaugural Cardiovascular Health Conference: conference findings and ways forward.
|
Heart Lung Circ
|
2010
|
0.76
|
|
54
|
Recommendations arising from the inaugural CSANZ Conference on Indigenous Cardiovascular Health.
|
Heart Lung Circ
|
2010
|
0.75
|
|
55
|
Design of a trial evaluating myocardial cell protection with cariporide, an inhibitor of the transmembrane sodium-hydrogen exchanger: the Guard During Ischemia Against Necrosis (GUARDIAN) trial.
|
Curr Control Trials Cardiovasc Med
|
2000
|
0.75
|
|
56
|
Further evidence that antithrombotic therapy is beneficial with streptokinase: improved early ST resolution and late patency with enoxaparin.
|
Eur Heart J
|
2002
|
0.75
|
|
57
|
See-sawing cardiovascular risk factors: a call for action in New Zealand.
|
N Z Med J
|
2006
|
0.75
|
|
58
|
'For Merit'--in medicine.
|
J R Soc Med
|
2002
|
0.75
|
|
59
|
Complimentary roles for N-terminal pro-B-type natriuretic peptide and spirometry to assess functional capacity in patients with complex mixed heart valve disease.
|
Kardiol Pol
|
2010
|
0.75
|
|
60
|
Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy.
|
Am Heart J
|
2007
|
0.75
|
|
61
|
Availability of troponin testing for cardiac patients in New Zealand 2002 to 2011: implications for patient care.
|
N Z Med J
|
2012
|
0.75
|
|
62
|
Coronary artery bypass graft surgery in New Zealand's Auckland region: a comparison between the clinical priority assessment criteria score and the actual clinical priority assigned.
|
N Z Med J
|
2006
|
0.75
|
|
63
|
Robin Mackenzie Norris.
|
N Z Med J
|
2015
|
0.75
|
|
64
|
Prasugrel, Māori, and personalised medicine in New Zealand.
|
N Z Med J
|
2010
|
0.75
|